|
See related Tasigna cap information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Nilotinib |
|
Indications |
Treatment of chronic & accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to at least 1 prior therapy.
Click to view Tasigna detailed prescribing infomation |
|
Dosage |
400 mg bd or 12 hrly.
Click to view Tasigna detailed prescribing infomation |
|
Overdosage |
View Tasigna overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Avoid food at least 2 hr before and at least 1 hr after a dose. Swallow whole, do not chew/crush. Avoid grapefruit products.). |
|
Contraindications |
Lactation.
Click to view Tasigna detailed prescribing infomation |
|
Special Precautions |
Myelosuppression. Patients who may develop QT prolongation eg those w/ hypokalaemia, hypomagnesaemia, congenital long QT syndrome, under antiarrhythmic medications & anthracycline therapy. Hepatic impairment. History of pancreatitis. Galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption. Perform CBC every 2 wk for the 1st 2 mth & then mthly thereafter. May impair ability to drive or operate machinery. Pregnancy.
Click to view Tasigna detailed prescribing infomation |
|
Adverse Drug Reactions |
Anorexia; headache; nausea, constipation, diarrhoea, vomiting, abdominal pain; rash, pruritus, alopecia; myalgia, arthralgia, muscle spasms, bone pain; fatigue, asthenia, peripheral oedema; febrile neutropenia, pancytopenia, hypomagnesaemia, hyperkalaemia, hyperglycaemia, insomnia, dizziness, paraesthesia, vertigo, palpitations, QT prolongation; HTN, flushing; GI, skin & SC tissue disorders; musculoskeletal chest pain; pyrexia; increased lipase; haematologic disorders.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors (contraindicated) & inducers; drugs eliminated by CYP3A4, CYP2C8, CYP2C9 & CYP2D6; antiarrhythmics eg amiodarone, disopyramide, procainamide, quinidine & sotalol or drugs that may lead to QT prolongation eg chloroquine, halofantrine, clarithromycin, haloperidol & methadone.
View more drug interactions with Tasigna |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Tasigna storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Tasigna description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Tasigna mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Special Feature |
For more information, see http://mims.asia/hk-tasigna |
|
